Stockscreener 앱 받기
2.33
2.10%
-0.05
시간 외 거래:
2.30
-0.03
-1.29%
전일 마감가:
$2.38
열려 있는:
$2.61
하루 거래량:
34,576
Relative Volume:
2.05
시가총액:
$10.14M
수익:
$12.84M
순이익/손실:
$-3.12M
주가수익비율:
-1.6973
EPS:
-1.3728
순현금흐름:
$-13.51M
1주 성능:
-14.00%
1개월 성능:
-19.10%
6개월 성능:
-39.32%
1년 성능:
-26.50%
1일 변동 폭
$2.30
$2.6799
1주일 범위
$2.28
$2.6899
52주 변동 폭
$2.28
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Compare BLRX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
2.33 | 10.36M | 12.84M | -3.12M | -13.51M | -1.3728 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2017-05-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-02-13 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-08-17 | 재확인 | Maxim Group | Buy |
| 2015-07-27 | 재확인 | ROTH Capital | Buy |
| 2015-06-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스
BioLineRx initiates Phase 1/2a study of GLIX1 - TipRanks
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Finviz
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma - TipRanks
BioLineRx launches trial of brain cancer drug GLIX1 - Investing.com
BioLineRx provides corporate update - TipRanks
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips By Investing.com - Investing.com South Africa
BioLineRx Reports 2025 Financial Results and Provides Corporate Update - Finviz
BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model - TipRanks
Going concern and debt pressures at BioLineRx (NASDAQ: BLRX) - Stock Titan
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings - Sahm
BioLineRx to Report 2025 Annual Results on March 23, 2026 - Finviz
BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute - TipRanks
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Beyond Air (XAIR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Radiopharm Theranostics Limited Sponsored ADR (RADX) and Resmed (RMD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA) - The Globe and Mail
BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges - MSN
BioLineRx Reports Q3 2025 Results and Strategic Expansion - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss By Investing.com - Investing.com South Africa
BioLineRx Announces Q3 2025 Financial Results and New Joint Venture - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss - Investing.com India
BioLineRx shares rise over 7% on better-than-expected earnings By Investing.com - Investing.com South Africa
BioLineRx shares rise over 7% on better-than-expected earnings - Investing.com
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Finviz
BioLine Rx's Earnings: A Preview - Sahm
BioLineRx stock rises after partner receives key patent allowance By Investing.com - Investing.com India
BioLineRx stock rises after partner receives key patent allowance - Investing.com
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - Finviz
BioLineRx stock rises after securing key patent for cancer treatment - Investing.com India
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - Finviz
BioLineRx Secures USPTO Patent Allowance for Cancer Treatment with GLIX1 - TipRanks
BioLineRx receives key patent for cancer treatment GLIX1 - Investing.com India
BioLineRx receives key patent for cancer treatment GLIX1 By Investing.com - Investing.com South Africa
Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Autolus Therapeutics (AUTL) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM) - The Globe and Mail
Working capital per share of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
BioLineRx ADR Earnings Call: Optimism Amid Challenges - MSN
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV) - The Globe and Mail
Cash per share of BioLineRX Ltd. Sponsored ADR – FWB:YP2 - TradingView
BioLineRx, Hemispherian AS establish joint venture to develop GLIX1 - TipRanks
BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma - TipRanks
BioLineRx and Hemispherian form joint venture to develop brain cancer drug - Investing.com
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - Sahm
BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), AnaptysBio (ANAB) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Bioline Rx Ltd Adr (BLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.04%
0.06%
자본화:
|
볼륨(24시간):